Skip to content
BHP

Peptides studied for Crohn's disease research

Last reviewed:

Crohn's disease research peptides target transmural inflammation, mucosal healing, and intestinal barrier dysfunction — with KPV's NF-κB-pathway suppression and BPC-157's mucosal angiogenesis effects as the principal pre-clinical hypotheses.

KPV encapsulated in nanoparticles reduced colonic inflammation in murine DSS-colitis models more effectively than the free tripeptide, raising research interest in delivery-system optimisation for gut-targeted peptide compounds.

— Notable finding

Condition background

Crohn's disease is a chronic, relapsing-remitting inflammatory bowel disease characterised by transmural granulomatous inflammation that can affect any segment of the gastrointestinal tract from mouth to anus, with terminal ileal involvement in approximately 70% of cases. UK prevalence is estimated at 145–230 per 100,000 population, with incidence increasing, particularly in younger age groups. The pathogenesis involves a dysregulated immune response to intestinal microbiota in genetically susceptible individuals, mediated through Th1 and Th17 T-cell pathways, innate immune defects (particularly NOD2/CARD15 variants), and impaired intestinal barrier function. Transmural inflammation leads to complications including strictures, fistulae, abscesses, and perianal disease. Mucosal healing — defined as normalisation of endoscopic appearance — is increasingly used as a therapeutic target beyond symptomatic remission, as it correlates with reduced hospitalisation and surgical rates.

Current treatment landscape

UK Crohn's disease management follows NICE technology appraisals and ECCO guidelines. Mild disease is typically managed with nutritional therapy (exclusive enteral nutrition, particularly in children) or aminosalicylates, though the evidence for the latter is limited. Corticosteroids induce remission in moderate-to-severe flares but are not appropriate for maintenance. Immunosuppressants — azathioprine, mercaptopurine, methotrexate — are used for maintenance of remission. Biological agents are the mainstay of moderate-to-severe disease: TNF-α inhibitors (infliximab, adalimumab) are first-line biologics; vedolizumab (anti-integrin) and ustekinumab (anti-IL-12/23) are alternatives. Janus kinase inhibitors are increasingly used. Surgery is indicated for complications and medically refractory disease.

Why peptides are studied here

Crohn's disease presents multiple targets for research peptides. Mucosal angiogenesis and epithelial repair: [BPC-157](/peptides/bpc-157) has demonstrated accelerated mucosal healing in rodent colitis models (DSS-induced and TNBS-induced), reducing macroscopic ulceration, restoring mesenteric blood flow, and lowering TNF-α and IL-6 in inflamed tissue. Its NO-modulating and VEGFR2-activating properties may address both the vascular insufficiency and the inflammatory milieu of Crohn's ulcers. Innate immune modulation: [KPV](/peptides/kpv) acts through melanocortin receptor-1 (MC1R) and direct intracellular NF-κB suppression to reduce pro-inflammatory cytokine release from macrophages and intestinal epithelial cells — mechanisms mechanistically aligned with the dysregulated innate immunity of Crohn's. Barrier restoration: [Larazotide](/peptides/larazotide) addresses the tight-junction dysfunction that permits luminal bacterial translocation, a key event in Crohn's relapse. Its ability to inhibit zonulin-mediated permeability increases without systemic immunosuppression makes it an interesting adjunct model in barrier-focused research.

Relevant research peptides

Notable study findings

  • BPC-157

    In DSS-induced rat colitis models, BPC-157 significantly reduced colonic inflammation scores, restored mesenteric microvascular blood flow, and decreased tissue TNF-α and IL-6 concentrations compared with vehicle controls, with effects observed across both oral and intraperitoneal dosing routes.

  • KPV

    KPV nanoparticle formulations reduced colonic inflammation in a murine DSS-colitis model, with significant reductions in inflammatory cytokines (IL-1β, TNF-α, IL-6) and improved colon length — a gross marker of colitis severity — compared with free KPV and vehicle controls.

  • Larazotide

    Larazotide reduced intestinal permeability and attenuated mucosal cytokine release in barrier-disruption models, with Phase II data from coeliac studies providing human mechanistic evidence applicable to Crohn's barrier dysfunction research.

Relevant research stacks

UK regulatory notes

BPC-157, KPV, and larazotide are not MHRA-licensed for Crohn's disease or any other indication in the UK. Larazotide has not received approval from the FDA or EMA despite Phase II human data. BPC-157 appears on the WADA Prohibited List under S0. This page is produced for laboratory research reference only and does not constitute medical or therapeutic guidance for Crohn's disease management.

Frequently asked questions

What is the difference between Crohn's disease and ulcerative colitis in research models?
Crohn's disease involves transmural inflammation that can affect any part of the GI tract, with granuloma formation; ulcerative colitis is limited to the colonic mucosa and submucosa in a continuous pattern. In rodent models, DSS (dextran sulphate sodium) colitis most closely mimics ulcerative colitis pathology, while TNBS (trinitrobenzene sulphonic acid) colitis produces a more transmural, granulomatous picture closer to Crohn's. BPC-157 has shown efficacy in both model types.
How does KPV suppress inflammation in the gut?
KPV (Lys-Pro-Val) acts through at least two mechanisms. Extracellularly, it binds melanocortin receptor-1 (MC1R) on immune cells, activating cAMP-mediated suppression of NF-κB signalling. At low pH — as might be found in inflamed gut — the tripeptide can cross epithelial cell membranes and directly inhibit IκB kinase within the cytoplasm, suppressing NF-κB activation from inside the cell. This dual pathway makes KPV of interest in conditions where mucosal NF-κB overactivation drives chronic inflammation.
Is BPC-157 specifically studied for Crohn's disease, or is the evidence extrapolated from general colitis models?
BPC-157's gut evidence comes primarily from DSS-colitis and NSAID-injury models in rodents, as well as ischaemia-reperfusion models. These do not perfectly replicate Crohn's transmural inflammation or its immunological drivers. The mechanistic rationale — mucosal angiogenesis, tight-junction preservation, anti-inflammatory cytokine modulation — is nonetheless relevant. There are no published Crohn's-specific human trials of BPC-157.
What is mucosal healing and why is it important as a research endpoint?
Mucosal healing refers to endoscopic normalisation of the bowel mucosa — absence of ulceration and restoration of normal vascular pattern. It has emerged as a preferred therapeutic target in Crohn's research because it correlates more strongly with sustained remission, reduced hospitalisation, and lower surgical rates than symptomatic endpoints alone. Research peptides that promote epithelial repair and vascular restoration are of interest in this context.
Can these peptides be used alongside biologic therapies in research models?
Combination models are technically feasible in pre-clinical research but are uncommon in the published peptide literature. The mechanistic complementarity of peptides (mucosal repair, barrier restoration) and biologics (systemic immune suppression) is conceptually interesting, but interaction studies have not been systematically conducted.
Is larazotide tested in Crohn's disease specifically?
Published clinical data for larazotide (AT-1001) focus primarily on coeliac disease, where it reduced gluten-induced intestinal permeability in Phase II trials. Crohn's disease-specific trials have not been published as of the date of this review. The zonulin-pathway mechanism is relevant to Crohn's, as intestinal barrier dysfunction is a feature of the condition and may contribute to relapse, but direct human Crohn's trial data are absent.

Where to source research peptides for laboratory research

The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.

  • PeptideAuthority.co.uk

    UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.

  • PeptideBarn.co.uk

    Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.